S&P Futures
4,357.75 -21.00 (-0.48%) Dow Futures
34,138.00 -135.00 (-0.39%) Nasdaq Futures
14,857.50 -77.75 (-0.52%) Russell 2000 Futures
1,789.50 -11.40 (-0.63%) Crude Oil
88.62 -1.06 (-1.18%) Gold
1,933.70 -2.90 (-0.15%)
DermTech, Inc. (DMTK)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.6500 |
| Open | 1.6400 |
| Bid | 0.0000 x 1200 |
| Ask | 0.0000 x 800 |
| Day's Range | 1.6000 - 1.6500 |
| 52 Week Range | 1.5500 - 6.4400 |
| Volume | |
| Avg. Volume | 272,746 |
| Market Cap | 54.897M |
| Beta (5Y Monthly) | 2.59 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.8000 |
| Earnings Date | Nov 01, 2023 - Nov 06, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.10 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for DMTK
Related Research
- DermTech, Inc.CELH: Lowering target price to $145.00CELSIUS HOLDINGS INC has an Investment Rating of SELL; a target price of $145.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.RatingFair ValueEconomic Moat6 days agoArgus Research
Business WireDermTech Grants New CCO Mark Aguillard Inducement Award Under NASDAQ Listing Rule 5635(c)(4)
SAN DIEGO, September 21, 2023--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that DermTech’s Compensation Committee has granted an equity award to its new chief commercial officer, Mark Aguillard. The award was granted pursuant to the terms of Mr. Aguillard’s employment letter and as a material inducement to his joining the Company as chief commercial officer.
Business WireDermTech Announces Contracts With Highmark for the Foundational Assay of Its DermTech Melanoma Test (DMT)
SAN DIEGO, September 19, 2023--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced agreements with Highmark Inc. (Highmark). The contracts, which are in addition to a favorable coverage policy, enhance access to the foundational assay of the DermTech Melanoma Test (DMT). Highmark and its Blue-branded affiliates provide health insurance to approximately 7 million members in Pennsylvania, Wes
GuruFocus.comInsider Sell: DermTech Inc CFO Kevin Sun Sells 9,616 Shares
On September 11, 2023, Kevin Sun, the Chief Financial Officer (CFO) of DermTech Inc (NASDAQ:DMTK), sold 9,616 shares of the company.
